Table 1 Baseline characteristics.
| Ā | Derivation, n (%) | Validation, n (%) | p value |
|---|---|---|---|
Number of patients | 69 | 70 | Ā |
Mean age in years, meanāĀ±āSD | 62.3āĀ±ā10.7 | 63.7āĀ±ā7.2 | 0.37 |
Number of biopsy samples | 69 | 70 | 0.87 |
Ā Obtained after the last line of treatment (ACT) | 36 (52.2) | 35 (50.0) | Ā |
Ā Obtained before the last line of treatment (BCT) | 33 (47.8) | 35 (50.0) | Ā |
Sex | Ā | Ā | 0.61 |
Ā Male | 40 (58.0) | 37 (52.9) | Ā |
Ā Female | 29 (42.0) | 33 (47.1) | Ā |
Histological subtypes | Ā | Ā | 0.31 |
Ā Squamous | 20 (29.0) | 21 (68.6) | Ā |
Ā Nonsquamous | 46 (66.7) | 48 (30.0) | Ā |
Ā Other (adenosquamous, LCNEC, NOS or unknown) | 3 (4.3) | 1 (1.4) | Ā |
ECOG performance score | Ā | Ā | 0.59 |
Ā 0 | 7 (10.1) | 8 (11.4) | Ā |
Ā 1 | 44 (63.8) | 40 (57.1) | Ā |
Ā ā„2 | 16 (23.2) | 22 (31.4) | Ā |
Ā Unknown | 2 (2.9) | 0 (0) | Ā |
DCB rate | Ā | Ā | 0.34 |
Ā Patients without DCB | 15 (21.7) | 21 (30.0) | Ā |
Ā Patients with DCB | 54 (78.3) | 50 (70.0) | Ā |
